Billy Evans and Haemanthus: A New Hope or the Shadow of Theranos?
Against the backdrop of the Theranos scandal and Elizabeth Holmes' imprisonment, public attention has turned to her husband, Billy Evans. Evans, who recently appeared in a documentary by Nathan Fielder and Lance Oppenheim, is currently leading his own startup, Haemanthus. The project aims to enable at-home analysis of blood, urine, and saliva, inevitably drawing comparisons to Theranos' failed ambitions. However, Evans categorically denies any connection to his wife's past work, insisting that Haemanthus operates with a fundamentally different approach.
Technological Differences and Laser Diagnostics
Unlike Theranos, which attempted to miniaturise existing diagnostic methods, Haemanthus utilises Raman spectroscopy. This scientific method works by directing laser beams at biological samples and analysing the vibrations of reflected photons. While this field has been actively researched in academic and scientific centres for years, integrating the technology into a consumer device while maintaining high accuracy presents significant engineering challenges.
Scepticism toward Haemanthus is largely driven by the Holmes factor, though independent experts note that the company's chosen path is scientifically grounded. The firm has already secured approximately $20 million in investment, yet it continues to operate in "stealth" mode. Evans has not disclosed product details, and no official company website exists, raising further questions among investors and observers.
Who is Billy Evans?
Originally from San Diego, Billy Evans is an heir to a well-known hotel chain. He studied economics at MIT and has worked for companies including LinkedIn and Luminar Technologies. His relationship with Elizabeth Holmes began in 2017, followed by high-profile legal proceedings and Holmes' incarceration. Although the couple appears together in the documentary discussing product ideas, Holmes' name does not appear in any official company documentation.
The company’s future plans are ambitious: once the laser system is refined, they intend to house the technology in a wearable device the size of a postage stamp. The company estimates this process will require three years and $70 million. While Haemanthus is currently focusing on veterinary diagnostics, regulatory oversight remains a primary hurdle.
Ultimately, the fate of Haemanthus depends on whether Evans' team can prove their technology is legitimate rather than a repetition of past failures. As Holmes prepares for her eventual release from prison, public interest in the couple remains high, though restoring trust in the tech world will prove far more difficult than developing the laser diagnostic system itself.